Nail incorporation kinetics of terbinafine in onychomycosis patients

被引:70
作者
Schatz, F
Brautigam, M
Dobrowolski, E
Effendy, I
Haberl, H
Mensing, H
Weidinger, G
Stutz, A
机构
[1] SANDOZ PHARMA AG,CLIN RES,NURNBERG,GERMANY
[2] HAUTKLIN MARBURG,DEPT DERMATOL,MARBURG,GERMANY
[3] HEWLETT PACKARD CORP,VIENNA,AUSTRIA
[4] HAUTKLIN EPPENDORF HAMBURG,DEPT DERMATOL,HAMBURG,GERMANY
关键词
D O I
10.1111/j.1365-2230.1995.tb01353.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Patients with toe-nail onychomycosis were treated with terbinafine (250 mg daily, n = 20) for either 6 or 12 weeks in a randomized double-blind study. Plasma and distal nail clippings were taken before initiation of therapy and 1, 6, 12, 18, 21, 36 and 48 weeks thereafter. Analytical data of terbinafine extracted from nail clippings or plasma were obtained by high-performance liquid chromatography (HPLC). Nail extracts and isolated HPLC terbinafine peaks were analysed using a combined gas chromatography-mass spectroscopy system (GC-MS) for unequivocal identification of the drug. Terbinafine could be detected in the distal nail in the majority of the patients within 1 week of starting therapy. Maximum terbinafine levels of 0.52 and 1.01 mu g/g were measured after 18 weeks in the 6- and 12-week treatment groups, respectively. While plasma levels decreased rapidly after termination of therapy terbinafine was detected in the nails as long as 30 weeks (6 weeks treatment) and 36 weeks (12 weeks treatment) after termination of therapy at a range of 0.28-0.19 mu g/g. The drug concentrations measured at all time points are well above the minimum inhibitory concentration (MIG) for dermatophytes and other fungi. These data suggest that the drug reaches the nail plate rapidly and persists there for several months after cessation of active treatment.
引用
收藏
页码:377 / 383
页数:7
相关论文
共 16 条
[1]   RELEVANCE OF BROAD-SPECTRUM AND FUNGICIDAL ACTIVITY OF ANTIFUNGALS IN THE TREATMENT OF DERMATOMYCOSES [J].
CLAYTON, YM .
BRITISH JOURNAL OF DERMATOLOGY, 1994, 130 :7-8
[2]   LEVELS OF TERBINAFINE IN PLASMA, STRATUM-CORNEUM, DERMIS EPIDERMIS (WITHOUT STRATUM-CORNEUM), SEBUM, HAIR AND NAILS DURING AND AFTER 250 MG TERBINAFINE ORALLY ONCE-DAILY FOR 7 AND 14 DAYS [J].
FAERGEMANN, J ;
ZEHENDER, H ;
MILLERIOUX, L .
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 1994, 19 (02) :121-126
[3]  
FINLAY AY, 1992, BRIT J DERMATOL, V126, P28, DOI 10.1111/j.1365-2133.1992.tb00006.x
[4]  
FINLAY AY, 1990, J DERMATOL TREAT S2, V1, P51, DOI DOI 10.3109/09546639009089035
[5]  
FINLAY AY, 1992, J DERMATOL TREAT S1, V3, P15
[6]  
GOODFIELD M, 1994, INT PERSPECTIVE LAMI, P64
[7]  
Jensen J, 1990, J DERMATOLOG TREAT, V1, P15
[8]  
MIETH H, 1993, CUTANEOUS ANTIFUNGAL, P137
[9]   ANTIFUNGAL ACTIVITY OF THE ALLYLAMINE DERIVATIVE TERBINAFINE INVITRO [J].
PETRANYI, G ;
MEINGASSNER, JG ;
MIETH, H .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1987, 31 (09) :1365-1368
[10]   PREVALENCE OF DERMATOPHYTE ONYCHOMYCOSIS IN THE UNITED-KINGDOM - RESULTS OF AN OMNIBUS SURVEY [J].
ROBERTS, DT .
BRITISH JOURNAL OF DERMATOLOGY, 1992, 126 :23-27